Monographie - Epirubicin hydrochloride

Dernière mise à jour :
19/11/2024

Epirubicin hydrochloride

Structure chimique

Noms commerciaux

Les noms commerciaux sont donnés à titre indicatif et la composition en excipients peut être différente selon les pays et selon les laboratoires

Anthracine	Malaisie
Axirubicine	Allemagne
Bendaepi	Allemagne
Binarin	Mexique
Bioepycina	Pologne
Crisabon	Argentine
Cuatroepi	Argentine
Ecclepia	Roumanie
Elebicin	Mexique
Ellence	Etats Unis d’Amérique
Epi Cell	Allemagne
Epidoxo	Argentine, Chili, Vénézuela
Epifil	Equateur
Epilem	Colombie, Mexique
Epimedac	Allemagne
Epirubicin	Arabie Saoudite, Australie, Autriche, Belgique, Danemark, Grande Bretagne, Hongrie, Islande, Nouvelle Zélande, Suède, Suisse, Turquie
Epirubicina	Argentine, Colombie, Equateur, Espagne, Mexique, Roumanie
Epirubicine	Belgique, France, Suisse
Farmarubicin	Turquie
Farmorubicin	Arabie Saoudite, Autriche, Brésil, Danemark, Finlande, Grèce, Norvège, Suède, Suisse
Farmorubicin CSV	Afrique du sud
Farmorubicin PFS	Croatie, Pologne, Slovénie
Farmorubicin RD	Brésil, Pologne, Russie, Suisse
Farmorubicin RTU	Pays bas
Farmorubicina	Brésil, Espagne, Italie, Portugal
Farmorubicine	Belgique, France
Pharmorubicin	Grande Bretagne

Bibliographie : Epirubicin hydrochloride

	Type	Source
148	Revue	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
525	Revue	De Vroe C, De Muynck C, Remon JP, Samsom M. A study on the stability of three antineoplastic drugs and on their sorption by IV delivery systems and end-line filters. Int J Pharm 1990 ; 65: 49-56.
683	Revue	Walker SE, Lau DWC, DeAngelis C, Iazetta J, Coons C. Epirubicin stability in syringes and glass vials and evaluation of chemical contamination. Can J Hosp Pharm 1990 ; 43: 265-272.
686	Revue	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
887	Revue	Pujol M, Munoz M, Prat J, Giona V, De Bolos J. Stability study of epirubicin in NaCl 0.9% injection. Ann Pharmacotherapy 1997 ; 31: 992-995.
1237	Revue	Keusters L, Stolk LML, Umans R, Van Asten P. Stability of solutions of doxorubicin and epirubicin in plastic minibags for intravesical use after storage at -20°C and thawing by microwave radiation. Pharm Weekbl [Sci] 1986 ; 8: 194-197.
1265	Revue	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1317	Revue	Adams PS, Haines-Hutt RF, Bradford E, Palmer A, Rowland CG. Pharmaceutical aspects of home infusion therapy for cancer patients. Pharm J 1987 ; 238: 476-478.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1823	Revue	Sewell GJ, Rigby-Jones AE, Priston MJ. Stability of intravesical epirubicin infusion: a sequential temperature study. J Clin Pharm Ther 2003 ; 28: 349-353.
1897	Revue	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1955	Revue	Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann Pharmacotherapy 2005 ; 39: 280-283.
2168	Revue	Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534.
2257	Laboratoire	Stability of epirubicin "Ebewe" infusion solutions. Ebewe Pharma 2007
3473	Revue	Bennis Y, Savry A, Correard F, Montana M, Sauzet C, Gauthier-Villano L, Pisano P, Pourroy B. Stability of a highly concentrated solution of epirubicin for conventional transcatheter arterial chemoembolization. Int J Pharm 2015 ; 495, 2: 956-962.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3632	Laboratoire	Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics Hospira 2017
3670	Revue	Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30.
3708	Poster	Sarakbi I, Thiesen J, Krämer I. Compatibility of epirubicin-loaded DC Beads with different contrast media. ECOP 2 Krakow 2014
3918	Revue	Sarakbi I, Krämer I. Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. J Oncol Pharm Practice 2016 ; 22: 749-756.
4352	Revue	Li J, Yao C, Xu Y, Ping P, Yin H, Sun Y. In vitro compatibility and stability of admixtures containing etoposide, epirubicin hydrochloride and vindesine sulphate in a single infusion bag. J Clin Pharm Ther 2019 ; 44: 875-882.

Mentions Légales